Abstract
Background Clinical guidelines recommend medications from four drug classes, collectively referred to as quadruple therapy, to improve outcomes for patients with heart failure with reduced ejection fraction (HFrEF). Wide gaps in uptake of these therapies persist across a range of settings. In this qualitative study, we identified determinants (i.e., barriers and facilitators of quadruple therapy intensification, defined as prescribing a new class or increasing the dose of a currently prescribed medication.
Methods We conducted interviews with physicians, nurse practitioners, physician assistants, and pharmacists working in primary care or cardiology settings in an integrated health system or Federally Qualified Health Centers (FQHCs). We report results with a conceptual model integrating two frameworks: 1) the Theory of Planned Behavior (TPB), which explains how personal attitudes, perception of others’ attitudes, and perceived behavioral control influence intentions and behaviors; and 2) The Consolidated Framework for Implementation Research (CFIR) 2.0 to understand how multi-level factors influence attitudes toward and intention to use quadruple therapy.
Results Thirty-one clinicians, including thirteen eighteen (58%) primary care and (42%) cardiology clinicians, participated in the interviews. Eight (26%) participants were from FQHCs. A common facilitator in both settings was the belief in the importance of quadruple therapy. Common barriers included challenges presented by patient frailty, clinical inertia, and time constraints. In FQHCs, primary care comfort and ownership enhanced the intensification of quadruple therapy while limited access to and communication with cardiology specialists presented a barrier. Results are presented using a combined TPB-CFIR framework to help illustrate the potential impact of contextual factors on individual-level behaviors.
Conclusions Determinants of quadruple therapy intensification vary by clinician specialty and care setting. Future research should explore implementation strategies that address these determinants by specialty and setting to promote health equity.
Competing Interest Statement
Dr. Ahmad reports receiving consulting fees and research funding from Pfizer outside of the submitted work. Dr. Persell receives research funding paid to Northwestern University from Omron Healthcare Co. Ltd. outside of the submitted work. Dr. Beidas is principal at Implementation Science & Practice, LLC. She is currently an appointed member of the National Advisory Mental Health Council and the NASEM study, Blueprint for a national prevention infrastructure for behavioral health disorders, and serves on the scientific advisory board for AIM Youth Mental Health Foundation and the Klingenstein Third Generation Foundation. She has received consulting fees from United Behavioral Health and OptumLabs. She previously served on the scientific and advisory board for Optum Behavioral Health and has received royalties from Oxford University Press. All activities are outside of the submitted work. The remaining authors report nothing to disclose.
Funding Statement
Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number K23HL155970.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Northwestern University Institutional Review Board approved this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are not available due as permission to share the data was not requested as part of the informed consent process.
Abbreviations
- HFrEF
- Heart Failure with reduced ejection fraction
- GDMT
- Guideline-directed medical therapy
- FQHC
- Federally-qualified Health Centers
- TPB
- Theory of Planned Behavior
- CFIR 2.0
- Consolidated Framework for Implementation Research 2.0
- COREQ
- Consolidated Criteria for Reporting Qualitative Research
- ACE inhibitors
- Angiotensin-Converting Enzyme Inhibitors
- ARBs
- Angiotensin II Receptor Blockers
- SGLT2i
- Sodium-Glucose Cotransporter-2 inhibitors
- ARNIs
- Angiotensin receptor/neprilysin inhibitors
- EHR
- Electronic health record
